Abbot Laboratories Stock Lower on Disappointing Forecast

Options bulls don't seem to be put off, however

Deputy Editor
Jul 20, 2022 at 10:34 AM
facebook twitter linkedin


Abbott Laboratories (NYSE:ABT) is down 1.7% to trade at $107.79 at last glance, despite the company's strong second-quarter earnings and revenue, both of which beat estimates. The health care concern's full-year profit forecast is weighing on shares, with analysts calling it "conservative." 

On the charts, ABT has been struggling to rebound from its June 17, nearly two-year low of $101.24, with recent pressure from the descending 50-day moving average. Year-to-date, the equity is down 23.5%. 

Analysts have yet to chime in with bear notes today, despite being less than enthused with ABT's modest forecast. There is plenty of room for pessimism, though, as all 11 in coverage sport a "buy" or better rating. 

Options traders, meanwhile, have been much more bearish than usual. This is per the security's 10-day put/call volume ratio of 2.81 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which stands in the 94th percentile of its annual range. 

A shift in sentiment appears to be occurring today, however. So far, 4,727 calls have been in exchange,  in comparison to 2,971 puts, with overall volume running at four times the intraday average. The weekly 7/22 110-strike call is the most popular, but positions are being opened at the weekly 7/29 110-strike call. 

 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners